Journal of IiMER Volume 13 Issue 1 Invest in ME Research focuses on the interface of nano-fabricated state devices and biological systems. He and his research team also develop no technologies for the genetic, genomic, and molecular analysis of a wide range of mo organisms as well as humans. The team's focus on practical application technologies is setting the standard for clin genomics. The genomic revolution has been spurred technological advances that made nucleo sequencing inexpensive, high-throughpu accessible. The next phase in this revolut the way for personalized health entails si breakthroughs in biosensor technologies personal molecular monitoring. Just as w sequencing, the key features to optimize accuracy, sensitivity, cost, and accessibili close collaboration between engineers, biochemists, geneticists, and clinicians, o has developed several such technologies devices. The technologies target the bioph properties of the cells and molecules, and do not rely on introducing labels or other c sample preparation techniques. We have successfully applied these technologies t drug resistance, resolving cells and molecules in bodily fluids and tissues, and engineering multiparametric, wearable biosensors. W begun applying these methods to unders chronic fatigue syndrome, one of the last diseases about which almost nothing is k anticipate that these technological break coupled with data integration of personal profiles will play an instrumental role in t realization of personalized health regimens and disease prevention strategies. Invest in ME Research (Charity Nr. 1153730) investinme.org Page 49 of 52

50 Publizr Home

You need flash player to view this online publication